Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16089862 | 1.00 | NPSR1 (0.43) | NPSR1GLO1ALOX15SOAT1ALDH1A1 | |
| SCHEMBL10621641 | 1.00 | NPSR1 (0.43) | NPSR1GLO1ALOX15SOAT1ALDH1A1 | |
| SCHEMBL3358511 | 0.83 | NPSR1 (0.41) | NPSR1GLO1ALOX15SOAT1ALDH1A1 | |
| SCHEMBL2951936 | 0.83 | HCAR2 (0.39) | ALDH1A1TSHRLMNASMN1; SMN2GAA | |
| SCHEMBL7601504 | 0.81 | NPSR1 (0.46) | NPSR1GLO1ALOX15SOAT1ALDH1A1 | |
| SCHEMBL7600152 | 0.81 | NPSR1 (0.46) | NPSR1GLO1ALOX15SOAT1ALDH1A1 | |
| SCHEMBL3355797 | 0.79 | FAAH (0.45) | NPSR1GLO1ALOX15ALDH1A1TSHR | |
| SCHEMBL14719757 | 0.79 | TSHR (0.41) | ALDH1A1TSHRHSD17B10SMN1; SMN2MEN1 | |
| SCHEMBL4351917 | 0.79 | ATM (0.48) | NPSR1ALDH1A1TSHRLMNAHSD17B10 | |
| SCHEMBL15641281 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114672267-B | Adhesive film, optical member including the same, and optical display including the same | 三星SDI株式会社 | 2024-03-12 | — | — | CN | disclosed |
| CN-116724095-A | Adhesive film, optical member including the same, and optical display device including the same | 三星SDI株式会社 | 2023-09-08 | — | — | CN | disclosed |
| EP-4213980-A1 | AMINE MODIFIED POLYSACCHARIDE URETHANE/UREA MICROCAPSULES | Encapsys, LLC (US) | 2023-07-26 | — | — | EP | disclosed |
| WO-2022061103-A1 | AMINE MODIFIED POLYSACCHARIDE URETHANE/UREA MICROCAPSULES | ENCAPSYS, LLC (US) | 2022-03-24 | — | — | WO | disclosed |
| US-20200392271-A1 | ASSOCIATIVE POLYMER STRUCTURES AND METHODS OF USE THEREOF | RHODIA OPERATIONS (FR) | 2020-12-17 | — | — | US | disclosed |
| US-9249179-B2 | Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA | Arrowhead Madison Inc. (US) | 2016-02-02 | — | — | US | disclosed |
| US-8993112-B2 | Polymeric particles | BASF SE (DE) | 2015-03-31 | — | — | US | disclosed |
| US-20120157509-A1 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR siRNA | ARROWHEAD RESEARCH CORPORATION | 2012-06-21 | — | — | US | disclosed |
| EP-1756184-B1 | POLYMERIC PARTICLES | BASF SE (DE) | 2010-01-13 | — | — | EP | disclosed |
| US-20070255008-A1 | Polymeric Particles | CIBA CORPORATION | 2007-11-01 | — | — | US | disclosed |
| EP-1756184-A1 | POLYMERIC PARTICLES | Ciba Specialty Chemicals Holding Inc. (CH) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005123796-A1 | POLYMERIC PARTICLES | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157509-A1 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR siRNA | GALK1, GALE, GALNT6 | NPSR1 1507/4885GLO1 366/4885ALOX15 3579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.